Actimab-P

N/A

Report date: 2025/11/14 17:20:11

Base Information

Drug NameActimab-P

Drug Alias NamePSMA-targeting mAb and Ac-225 conjugate (Actinium Pharmaceuticals)J591-Ac-225

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[5]

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A